Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Size

• The Europe Circulating Tumor Cells (CTC) liquid biopsy market size was valued at USD 838.01 million in 2025and is expected to reach USD 4,775.49 million by 2033, at a CAGR of 24.3% during the forecast period
• The market growth is largely fueled by the increasing adoption of minimally invasive cancer diagnostics and rapid advancements in liquid biopsy technologies, leading to improved early cancer detection and real-time disease monitoring across oncology care settings in Europe
• Furthermore, rising demand for precision medicine, coupled with growing clinical validation and integration of CTC-based testing in personalized treatment strategies, is establishing liquid biopsy as a key diagnostic approach. These converging factors are accelerating the uptake of CTC liquid biopsy solutions, thereby significantly boosting the industry's growth

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Analysis

• Circulating Tumor Cells (CTC) liquid biopsy, a minimally invasive cancer diagnostic approach, is gaining strong importance in oncology due to its ability to enable real-time cancer monitoring, early detection, and advanced tumor characterization through blood-based sampling, reducing reliance on invasive tissue biopsies
• The escalating demand for Europe Circulating Tumor Cells (CTC) liquid biopsy is primarily fueled by the rising cancer burden across Europe, increasing adoption of precision oncology, and growing clinical preference for advanced molecular diagnostic tools that improve treatment decision-making and patient outcomes
• Germany dominated the Europe Circulating Tumor Cells (CTC) liquid biopsy market with the largest revenue share of 34.6% in 2025, supported by strong oncology research infrastructure, high healthcare spending, and widespread adoption of advanced diagnostic technologies, with the country playing a key role in clinical trials and commercialization of CTC-based testing solutions across leading research institutes and hospitals
• The United Kingdom is expected to be the fastest growing country in the Europe Circulating Tumor Cells (CTC) liquid biopsy market during the forecast period, holding a significant growth momentum, due to strong government support for cancer research, rapid adoption of liquid biopsy in clinical oncology, and increasing integration of genomic and precision medicine approaches in NHS-driven cancer care pathways
• The CTC detection methods segment dominated the Europe Circulating Tumor Cells (CTC) liquid biopsy market with a market share of 42.8% in 2025, driven by its high clinical relevance in identifying rare tumor cells in blood samples and its broad utilization in cancer monitoring, prognosis evaluation, and treatment response assessment across oncology applications

Report Scope and Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Segmentation

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Trends

“Advancement Toward Multi-Omics and AI-Driven Liquid Biopsy Integration”

• A significant and accelerating trend in the Europe Circulating Tumor Cells (CTC) liquid biopsy market is the integration of multi-omics technologies with AI-powered diagnostic platforms to improve cancer detection accuracy and real-time tumor profiling in oncology workflows
• For instance, CTC-based assays integrated with next-generation sequencing (NGS) platforms are increasingly being used in Europe to combine genomic, transcriptomic, and proteomic data for more comprehensive cancer characterization
• AI integration in CTC liquid biopsy enables advanced pattern recognition for rare tumor cell detection, improves predictive analytics for treatment response, and enhances automation in image-based CTC identification systems used in oncology laboratories
• The seamless integration of CTC analysis with digital pathology and bioinformatics platforms is enabling centralized cancer data interpretation, allowing clinicians to make faster and more precise personalized treatment decisions across European healthcare systems
• This trend towards highly integrated, data-driven liquid biopsy solutions is reshaping oncology diagnostics, with companies developing automated CTC enrichment and detection systems that support high-throughput and clinically scalable cancer monitoring
• The demand for advanced CTC liquid biopsy platforms with AI and multi-omics integration is growing rapidly across European oncology centers as precision medicine adoption continues to expand in clinical cancer management
• Furthermore, microfluidic-based CTC isolation technologies are gaining traction due to their higher sensitivity and ability to capture rare tumor cells with improved efficiency compared to conventional enrichment methods

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Dynamics

Driver

“Rising Cancer Prevalence and Shift Toward Precision Oncology Diagnostics”

• The increasing burden of cancer cases across Europe, coupled with the rapid shift toward precision oncology, is a significant driver for the growing adoption of Circulating Tumor Cells (CTC) liquid biopsy solutions in clinical diagnostics
• For instance, in April 2025, several European oncology research institutes expanded clinical trials using CTC-based assays to improve early cancer detection and treatment monitoring in breast and lung cancer patients
• As clinicians increasingly prioritize minimally invasive diagnostic tools, CTC liquid biopsy offers real-time insights into tumor evolution, enabling personalized treatment adjustments without repeated tissue biopsies
• Furthermore, growing investments in cancer research and strong support from European healthcare systems are accelerating the integration of CTC technologies into routine oncology workflows
• The convenience of repeatable blood-based sampling for disease monitoring and treatment response evaluation is a key factor driving adoption of CTC liquid biopsy across hospitals and diagnostic laboratories in Europe
• For instance, national cancer screening initiatives in several European countries are increasingly evaluating liquid biopsy tools for early detection of metastatic risk in high-risk patient populations
• Additionally, rising collaboration between biotech firms and academic research institutions is accelerating innovation and clinical validation of advanced CTC detection platforms across Europe

Restraint/Challenge

“High Technical Complexity and Limited Standardization Across Clinical Platforms”

• Concerns surrounding the technical complexity of isolating and analyzing rare circulating tumor cells, along with lack of standardized clinical protocols, pose a significant challenge to widespread adoption of CTC liquid biopsy in Europe
• For instance, variability in CTC detection methods such as microchips, immunocytochemical technologies, and negative selection techniques often leads to inconsistent clinical results across different laboratories
• Additionally, the need for highly specialized equipment and skilled personnel increases operational costs, limiting accessibility for smaller diagnostic centers and hospitals in certain European regions
• The absence of universally accepted clinical guidelines for CTC interpretation further restricts routine integration into standard oncology practice despite strong research interest
• While ongoing advancements in automation and enrichment technologies are improving reliability, the current lack of harmonization across platforms continues to slow large-scale clinical deployment
• Overcoming these challenges through standardization of testing protocols, regulatory alignment, and cost-effective technology development will be critical for sustained market expansion in Europe
• For instance, differences in regulatory approval timelines across European countries delay uniform adoption of advanced CTC-based diagnostic systems in clinical settings
• Furthermore, limited reimbursement coverage for liquid biopsy procedures in some healthcare systems continues to restrict patient access and broader commercialization potential

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope

The market is segmented on the basis of technology, application, and end user.

• By Technology

On the basis of technology, the Europe Circulating Tumor Cells (CTC) liquid biopsy market is segmented into CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection, and Immunocytochemical Technologies. The CTC Detection Methods segment dominated the market with the largest revenue share of 42.8% in 2025, driven by its critical role in identifying rare circulating tumor cells in blood samples with high sensitivity and clinical reliability. These methods are widely used in oncology for cancer screening, prognosis assessment, and monitoring treatment response. Their strong clinical validation across multiple cancer types supports widespread adoption in hospitals and research centers across Europe. Increasing demand for early cancer detection and non-invasive diagnostics further strengthens this segment’s dominance. Continuous improvements in detection accuracy and automation are also enhancing clinical acceptance.

The Microchips segment is expected to witness the fastest growth rate of 22.4% from 2026 to 2033, driven by advancements in microfluidic engineering that enable precise and efficient isolation of circulating tumor cells. These technologies offer higher sensitivity, faster processing time, and improved cell viability compared to conventional methods. Their ability to handle small sample volumes with high accuracy makes them highly suitable for advanced oncology research. Growing adoption in precision medicine and personalized cancer treatment is accelerating demand for microchip-based platforms. Increasing investment in lab-on-a-chip innovations across Europe is further supporting market expansion. Additionally, integration with AI-based imaging systems is improving detection efficiency and clinical usability.

• By Application

On the basis of application, the Europe Circulating Tumor Cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities, and others. The Cancer Stem Cell Research segment dominated the market with the largest revenue share of 48.1% in 2025, driven by its critical role in understanding tumor initiation, metastasis, and therapy resistance. CTCs are widely used in research studies to analyze cancer stem cell behavior and its contribution to disease recurrence. Strong funding support for oncology research in Europe is further boosting this segment’s dominance. Academic institutions extensively use CTC-based platforms for biomarker discovery and drug development studies. Increasing focus on precision oncology and targeted therapies also supports high adoption. Growing collaborations between research centers and biotech firms are accelerating innovation in this application area.

The Multiple Chromosome Abnormalities segment is expected to witness the fastest growth rate of 20.9% from 2026 to 2033, driven by rising use of genomic profiling in cancer diagnostics. This application helps in identifying chromosomal instability and tumor heterogeneity, which are key indicators of cancer progression. Integration of CTC analysis with next-generation sequencing technologies is enhancing its diagnostic value. Increasing adoption of personalized medicine approaches is also supporting segment growth. Rising demand for advanced prognostic tools in oncology is further boosting utilization. Additionally, expanding clinical research focused on genetic mutations in cancer patients is accelerating adoption across Europe.

• By End User

On the basis of end user, the Europe Circulating Tumor Cells (CTC) liquid biopsy market is segmented into research & academic institutes, reference laboratories, and hospitals & physician laboratories. The Research & Academic Institutes segment dominated the market with the largest revenue share of 51.6% in 2025, driven by extensive use of CTC technologies in oncology research, biomarker identification, and clinical trial studies. These institutes play a central role in advancing liquid biopsy innovation and validating new diagnostic applications. Strong government and private funding for cancer research in Europe further supports dominance. High collaboration between universities and biotechnology companies is also enhancing research output. Increasing focus on early cancer detection technologies strengthens demand. Continuous development of novel CTC analysis techniques keeps this segment highly active.

The Hospitals & Physician Laboratories segment is expected to witness the fastest growth rate of 23.1% from 2026 to 2033, driven by increasing clinical adoption of liquid biopsy in routine cancer diagnostics. Growing preference for minimally invasive testing methods is encouraging hospitals to integrate CTC-based diagnostics into oncology workflows. Rising implementation of precision medicine programs across European healthcare systems is also supporting growth. Improvements in laboratory infrastructure and automation are enhancing testing capacity. Increasing awareness among clinicians regarding real-time cancer monitoring is further driving adoption. Expansion of hospital-based molecular diagnostic services is accelerating market penetration in clinical settings.

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Regional Analysis

• Germany dominated the Europe Circulating Tumor Cells (CTC) liquid biopsy market with the largest revenue share of 34.6% in 2025, supported by strong oncology research infrastructure, high healthcare spending, and widespread adoption of advanced diagnostic technologies
• Healthcare providers and research organizations in Germany highly value CTC liquid biopsy for its non-invasive nature, ability to enable real-time cancer monitoring, and strong clinical utility in early cancer detection, prognosis assessment, and treatment response evaluation
• This widespread adoption is further supported by robust healthcare infrastructure, high R&D investments in oncology, and strong collaboration between academic institutes, hospitals, and biotechnology companies, establishing Germany as a key hub for liquid biopsy innovation in Europe

The Germany Circulating Tumor Cells (CTC) Liquid Biopsy Market Insight

The Germany Circulating Tumor Cells (CTC) liquid biopsy market captured the largest revenue share of 34.6% in Europe in 2025, driven by its highly advanced oncology research ecosystem and strong focus on precision medicine adoption. Germany has a well-established healthcare infrastructure that supports early adoption of innovative diagnostic technologies, particularly in cancer detection and monitoring. Increasing use of CTC-based liquid biopsy in clinical trials and hospital diagnostics is further strengthening market leadership. Additionally, strong government and private R&D investments in oncology are accelerating technology development and commercialization across the country.

U.K. Circulating Tumor Cells (CTC) Liquid Biopsy Market Insight

The U.K. Circulating Tumor Cells (CTC) liquid biopsy market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing focus on early cancer detection and expanding adoption of precision oncology approaches. Rising awareness of non-invasive diagnostic techniques is encouraging broader clinical use of liquid biopsy solutions across healthcare settings. The country’s strong participation in oncology research and clinical trials is further supporting market growth. Additionally, integration of CTC-based diagnostics into national healthcare pathways is improving accessibility and strengthening adoption in hospitals and laboratories.

France Circulating Tumor Cells (CTC) Liquid Biopsy Market Insight

The France Circulating Tumor Cells (CTC) liquid biopsy market is expected to expand at a considerable CAGR during the forecast period, fueled by growing investment in cancer research and increasing adoption of advanced molecular diagnostic technologies. France has a strong oncology research base that supports development and validation of liquid biopsy applications in clinical practice. Rising demand for personalized cancer treatment is further driving the use of CTC technologies in hospitals and research institutions. Additionally, government initiatives promoting innovation in healthcare diagnostics are supporting market expansion across the country.

Italy Circulating Tumor Cells (CTC) Liquid Biopsy Market Insight

The Italy Circulating Tumor Cells (CTC) liquid biopsy market is projected to grow steadily during the forecast period, supported by increasing awareness of early cancer detection and rising adoption of minimally invasive diagnostic tools. The country is witnessing gradual integration of liquid biopsy technologies into oncology research and clinical workflows. Expanding focus on precision medicine and biomarker-based cancer diagnostics is further supporting market growth. Additionally, increasing collaboration between academic research centers and healthcare providers is enhancing adoption of CTC-based testing solutions.

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Share

The Europe Circulating Tumor Cells (CTC) Liquid Biopsy industry is primarily led by well-established companies, including:

• QIAGEN (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Illumina, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Menarini Silicon Biosystems S.p.A. (Italy)
• ANGLE plc (U.K.)
• Greiner Bio-One International GmbH (Austria)
• Miltenyi Biotec B.V. & Co. KG (Germany)
• RareCyte, Inc. (U.S.)
• Biolidics Limited (Singapore)
• Bio-Techne Corporation (U.S.)
• Exact Sciences Corporation (U.S.)
• Myriad Genetics, Inc. (U.S.)
• NeoGenomics Laboratories, Inc. (U.S.)
• Oncocyte Corporation (U.S.)
• Lucence Health Inc. (Singapore)
• Vortex Biosciences, Inc. (U.S.)
• Guardant Health, Inc. (U.S.)

What are the Recent Developments in Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market?

• In May 2025, NHS England expanded liquid biopsy–based cancer testing for lung and breast cancer patients, using circulating tumor DNA (ctDNA) to accelerate treatment decisions and reduce reliance on invasive tissue biopsies. The initiative enables faster genomic profiling of tumors, allowing clinicians to tailor therapies more efficiently and improve patient outcomes. This rollout highlights Europe’s growing shift toward integrating liquid biopsy technologies into routine clinical oncology practice
• In March 2025, a European research consortium introduced deep learning–based automated systems for CTC identification in liquid biopsy samples, significantly improving classification accuracy of tumor cells versus normal blood cells. The approach reduces manual workload and enhances diagnostic consistency across laboratories. This advancement supports broader clinical adoption of AI-driven liquid biopsy workflows in Europe
• In January 2025, researchers published advances in high-throughput microfluidic technologies for circulating tumor cell (CTC) enrichment, enabling more efficient capture and genomic analysis of rare cancer cells from blood samples. The study demonstrated improved sensitivity for detecting heterogeneous tumor populations and supporting comprehensive cancer monitoring. This development strengthens Europe’s capability in precision oncology and next-generation liquid biopsy platforms.
• In October 2024, scientists developed a fully automated machine learning pipeline for detecting circulating tumor cells in metastatic breast cancer patients, achieving high sensitivity and specificity in large-scale blood sample analysis. The system reduced millions of blood cells into a small subset of candidate CTCs for clinical review, improving efficiency in oncology diagnostics. This innovation represents a key step toward scalable liquid biopsy deployment in European cancer care
• In November 2024, European researchers proposed a human-in-the-loop AI strategy to improve CTC detection accuracy by combining expert validation with machine learning models for liquid biopsy data analysis. The study showed improved performance in detecting rare tumor cells in metastatic breast cancer samples. This hybrid approach is increasingly important in Europe for overcoming limitations in fully automated CTC detection systems

SKU-66916